
- Drug Development
- - Drug-drug interaction
- - Evaluation of drug metabolism
- - Drug mediated responses
- Toxicity
- - Hepatotoxicity
- - Detoxification effects
- - Uptake and efflux transporter activities
- Enzyme activity
- - Assessment of potential enzyme induction or inhibition
- Show More
- Cell metabolism
- - Metabolic pathway identification
- - Metabolic profiling
- - Metabolism of stable compounds
- - Determination of metabolic routes in metabolite formation
- - Assessment of effects on hepatocellular functions
- - Assessment of protection against cancer(reactive oxygen species)
- Show More


- Drug Development
- - Drug-drug interaction
- - Evaluation of drug metabolism
- - Drug mediated responses
- Toxicity
- - Hepatotoxicity
- - Detoxification effects
- - Uptake and efflux transporter activities
- Enzyme activity
- - Assessment of potential enzyme induction or inhibition
- Show More
- Cell metabolism
- - Metabolic pathway identification
- - Metabolic profiling
- - Metabolism of stable compounds
- - Determination of metabolic routes in metabolite formation
- - Assessment of effects on hepatocellular functions
- - Assessment of protection against cancer(reactive oxygen species)
- Show More
Cryopreserved Human Hepatocytes - 3D Qualified and Induction Certified - All Cells are suited for 3D spheroid cultures on 24 and 96 well plates.
Cryopreserved hepatocytes are characterized for CYP450 and Phase II drugmetabolizing enzyme activity.
-2021 -0330
Product Code Lot No. |
|
Available Vials /Gender |
Viability after Thawing (%) Age/BMI |
Mio Cells / Vial (Mean +/- Std |
EUR/Vial |
---|---|---|---|---|---|
HuHeCPMI/6+ BHum16061 |
9 / 9 |
2 |
89 % |
8.9 +/- 1.5 |
999.00 |
HuHeCPMI/6+ BHum16059 |
7 / 6 |
23 |
88 % |
6.6 +/- 2.1 |
999.00 |
HuHeCPMI/6+ BHum16023 |
10 / 7 |
30 |
83 % |
8.0 +/- 3.5 |
999.00 |
HuHeCPMI/6+ BHum16016 |
Pending |
2 |
90 % |
9.5 +/- 1.3 |
999.00 |
HuHeCPMI/6+ BHum16007 |
9 / 7 |
5 |
86 % |
12.4 +/- 2.7 |
999.00 |
HuHeCPMI/4+ BHuf16057 |
10 / 6 |
14 |
85 % |
6.5 +/- 4.9 |
670.00 |
HuHeCPMI/4+ BHuf16068 |
12 / 12 |
8 |
87 % |
5.5 +/- 1.1 |
670.00 |
HuHeCPMI/4- BHuf16087 |
20 / 18 |
58 |
90 % |
3.2 +/- 14.6 |
440.00 |
Cryopreserved Human Hepatocytes - Suited for 24 and 96 Well Plates, not for 3D Applications / Induction Certified.
Cryopreserved hepatocytes are characterized for CYP450 and Phase II drugmetabolizing enzyme activity.
-2021 -0415
Product Code Lot No. |
|
Available Vials /Gender |
Viability after Thawing (%) Age/BMI |
Mio Cells / Vial (Mean +/- Std |
EUR/Vial |
---|---|---|---|---|---|
HuHeCPMI/4+ BHum16006 |
10/7 |
62 |
83 % |
6.5 +/- 2.1 |
642.00 |
HuHeCPMI/4+ BHum5052 |
10 / not tested |
53 |
78%/ |
5.0 +/- 1.7 |
642.00 |
HuHeCPMI/4- BHum16035 |
15/4 |
157 |
82 % |
3.2 +/- 1.6 |
420.00 |
HuHeCPMI/4- BHuf16029 |
13/4 |
229 |
89 % |
4.0 +/- 0.7 |
420.00 |